Zhou XC, Hou X, Jin F, Podratz KC et al. Histone deacetylase inhibitors and paclitaxel result in synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006; 5: 2767?776. 42. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007; 30: 1181?188. 43. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291?300. 44. Muhlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent improve in the pro- to anti-apoptotic proteins ratio. BMC Cancer 2006; 6: 214. 45. Chung YL, Wang AJ, Yao LF. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic get in cancer radiotherapy. Mol Cancer Ther 2004; 3: 317?25. 46. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L et al. Restoring E-cadherin expression increases sensitivity to epidermal growth element receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66: 944?50. 47. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 2011; 13: 566?79. 48. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986?997. 49. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.4,4′-Diphenyl-2,2′-bipyridine site Response to epidermal growth element receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis related to persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.Buy89284-85-5 Clin Cancer Res 2003; 9: 2316?326.PMID:23074147 50. Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S et al. EGFR-TKI resistance on account of BIM polymorphism could be circumvented in combination with HDAC inhibition. Cancer Res 2013; 73: 2428?434. 51. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL et al. Randomized phase II trial of erlotinib with and with no entinostat in individuals with sophisticated non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012; 30: 2248?255. 52. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006; 12: 4377s?383s. 53. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X et al. Constitutively active variety I insulin-like growth aspect receptor causes transformation and xenograft development of immortalized mammary epithelial cells and is accompanied by an epithelialto-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 2007; 27: 3165?175. 54. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, Andrac-Meyer L et al. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer 2007; 96: 329?35. 55. Ma Pc, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD et al. c-MET mutational evaluation in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. C.
